The U.S. Food and Drug Administration (FDA) recently released a guidance on "Time and Extent Applications for Nonprescription Drug Products" (the "Guidance"). The Guidance describes the FDA's latest thinking on the information applicants should provide when requesting that conditions be added to the FDA's over-the-counter (OTC) drug monograph system. Specifically, the Guidance focuses on the time-and-extent application (TEA) component of the monograph application process, which requires applicants to demonstrate that the condition has been marketed OTC to a material extent and for a material time. The Guidance applies to any OTC drug that does not have any marketing experience in the United States or that is initially marketed in the United States after May 11, 1972, when the OTC drug review started.

As the first of two steps in the OTC drug monograph system inclusion process, the TEA must include information about the OTC condition. For example, this would include:

  • The intended OTC uses, strengths or dosage forms;
  • A list of all countries in which the condition has been marketed; and
  • Information on the marketing activities in those countries, including demographics; dosage-unit sales history; and the country's system for identifying adverse drug experiences.

The TEA applicant also needs to include English versions of the product labels from every country in which the condition is marketed. Applicants submitting a TEA for an OTC drug marketed for more than five years under an FDA-approved application are exempt from some of these requirements.

The Guidance further advises that after submission, TEA applicants can anticipate eligibility determinations within one year. If the condition is found eligible for inclusion on the OTC drug monograph system, a notice will be published in the Federal Register and the TEA will be publicly displayed. Applicants found ineligible will receive a publicly displayed letter from the FDA stating why the condition was not eligible. Rejected TEAs, however, will not be publicly displayed.

If you have any questions about this Alert, please contact Frederick R. Ball, any member of the Pharmaceutical, Pharmacy & Food industry group or the attorney in the firm with whom you are regularly in contact.

This article is for general information and does not include full legal analysis of the matters presented. It should not be construed or relied upon as legal advice or legal opinion on any specific facts or circumstances. The description of the results of any specific case or transaction contained herein does not mean or suggest that similar results can or could be obtained in any other matter. Each legal matter should be considered to be unique and subject to varying results. The invitation to contact the authors or attorneys in our firm is not a solicitation to provide professional services and should not be construed as a statement as to any availability to perform legal services in any jurisdiction in which such attorney is not permitted to practice.

Duane Morris LLP, a full-service law firm with more than 700 attorneys in 24 offices in the United States and internationally, offers innovative solutions to the legal and business challenges presented by today's evolving global markets. Duane Morris LLP, a full-service law firm with more than 700 attorneys in 24 offices in the United States and internationally, offers innovative solutions to the legal and business challenges presented by today's evolving global markets. The Duane Morris Institute provides training workshops for HR professionals, in-house counsel, benefits administrators and senior managers.